Earnings Call
Apr 29, 2026
Q1 FY2026
EPS Estimate
2.59
EPS Actual
2.65
Post-Earnings Close
$203.89
Earnings Reaction
+3.1%
AbbVie's first quarter of 2026 was defined by the continued compounding of its post-HUMIRA growth engine, with Skyrizi and Rinvoq together generating momentum that is now outpacing even the company's own elevated expectations. Total net revenues of $15 billion grew 12.4% and beat guidance by $300 million, while adjusted EPS of $2.65 cleared the midpoint by $0.07. The strength was broad-based enough that management raised full-year adjusted EPS guidance by $0.12 to a range of $14.08, $14.28 and lifted the revenue outlook to approximately $67.3 billion, with incremental uplifts across Skyrizi, Rinvoq, and neuroscience. Critically, management reiterated, with notable conviction, that sell-side consensus continues to underestimate peak potential for both immunology flagships, with Skyrizi consensus around $33 billion and Rinvoq around $16 billion in 2031 both described as floors rather than ceilings.
Report generated on May 1, 2026
AI-generated earnings analysis. Not investment advice.
Chief Executive Officer
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
Read the full ABBV analysis
The complete report, with key themes, analyst Q&A summary, notable quotes, and market context — is free with an account. No password, no card.